Palbociclib, ribociclib, and abemaciclib are the three FDA-approved CDK4/6is for breast cancer, which are currently the first- and second-line systemic treatment choices for HR+/human epidermal growth factor-2 negetive (HER2-) advanced/metastatic BC. Here, CDK4 is linked to breast cancer.